Navigation Links
Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer
Date:9/10/2007

TUSTIN, Calif., Sept. 10 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and hepatitis C virus (HCV) infection, today announced that it has submitted a clinical protocol with the Drug Controller General of India (DCGI) for an open label Phase II safety and efficacy trial of bavituximab in combination with the chemotherapy drugs paclitaxel and carboplatin in patients with metastatic breast cancer. The multi-center trial is expected to begin enrolling patients pending regulatory and ethics committee approvals.

The trial has a two-stage design. Up to 15 patients with metastatic breast cancer will be enrolled initially and the study will be expanded up to a total of 46 patients if promising results are observed in the first cohort. The primary objective is to assess the overall response rate to the combination of bavituximab with doses of paclitaxel and carboplatin. Secondary objectives include measuring time to tumor progression, duration of response, overall patient survival and safety parameters. Patients may continue to receive weekly administration of bavituximab with weekly doses of paclitaxel and carboplatin as long as their cancer does not progress, unless side effects require earlier cessation of therapy.

"The filing of this second cancer clinical protocol reflects our strategy of fielding a number of targeted Phase II combination studies in specific cancer indications," said Steven W. King, president and CEO of Peregrine. "Despite advances in treatment, breast cancer remains a major source of mortality among women. We designed this study using data generated from our recen
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Peregrine Pharmaceuticals Reports Positive Top-Line Results in Bavituximab Combination Therapy Trial in Advanced Cancer Patients
2. Positive Results Using Affitech-Identified Human Antibody That Blocks VEGF Binding to VEGF Receptor 2 in Preclinical Cancer Model Reported by Peregrine
3. Peregrine Pharmaceuticals Highlights Significant Advances in the Companys Clinical and Preclinical Cancer Programs Presented This Week at the AACR Annual Meeting
4. Data Presented at AACR Meeting Shows Peregrines Immunocytokine Fusion Proteins Reduce Growth of B-Cell Lymphoma Tumors by 85% in Preclinical Studies
5. Data Presented at AACR Meeting Show Peregrines Bavituximab Equivalent Can Generate Curative Immune Responses as Part of a Vaccine-Like Regimen in Preclinical Models of Aggressive Brain Cancer
6. Data Presented at AACR Meeting Shows Peregrines Selective Anti-VEGF Antibodies are as Effective as Avastin(R) in Preclinical Cancer Models
7. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... York , July 11, 2014 ... Transparency Market Research "Endoscopy Devices Market (Endoscopes, Endoscopic Operative ... Share, Growth, Trends and Forecast, 2013-2019" the global endoscopy ... 2012 and is expected to grow at a CAGR ... estimated value of USD 36.9 billion in 2019. ...
(Date:7/11/2014)... 2014 Show organisers ... Health Expo 2014 were a brand new ... London , plus a 10% ...        (Logo: http://photos.prnewswire.com/prnh/20130723/629764-a) ...      (Photo: http://photos.prnewswire.com/prnh/20140711/696892-b ...
(Date:7/10/2014)... NEWS, Virginia , 11. Juli ... Hersteller von Kameras für die molekulare ... (MBI/BSGI), hat heute die CE-Zulassung für ... dem CE-Zeichen kann Dilon das Produkt ... Vertriebsbereich auf den Großteil der europäischen ...
Breaking Medicine Technology:Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 2Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 4Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 5Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 6UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 2UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 3UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 4Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2
... Kendle (Nasdaq: KNDL ), a leading, global full-service clinical research organization, today ... on June 23, 2010 , at the InterContinental Hotel in Boston . ... Kendle,s formal presentation will be given by Chairman ... Time . , , , ...
... June 17 Brainlab AG today announced that it ... business unit of the Toshiba Group, to integrate its Aquilion™ LB ... operating room (OR). , , ... Stephan Holl , Chief Operating Officer, Brainlab, indicated that ...
Cached Medicine Technology:Kendle to Present at 2010 Wells Fargo Securities Healthcare Conference 2Brainlab Collaborates With Toshiba Medical Systems on Integrated Surgical Suite 2Brainlab Collaborates With Toshiba Medical Systems on Integrated Surgical Suite 3
(Date:7/11/2014)... benefit from being prescribed exercise as medicine, according ... high intensity activity is essential to reducing the ... Debra Anderson, from QUT,s Institute of Health and ... treatments for physical and mental health, health professionals ... women. , Professor Anderson and QUT,s Dr Charlotte ...
(Date:7/11/2014)... University has revealed that people who have grown up ... likely as their urban counterparts to develop the most ... The study findings have recently been published in the ... extremely exciting that we can now see that not ... appear to depend on the environment we are exposed ...
(Date:7/11/2014)... Emily Johnson, owner of the Portland Fit Body Boot Camp, ... has held two charity workout events and is about to ... 7:15 - 8:30 at Col Summers City Park, SE 20th and ... raised $510 for Medical Teams International. Their second workout event resulted ... On July 26th, Johnson and Portland Fit Body Boot Camp ...
(Date:7/11/2014)... Recently, iFitDress.com, a leading online supplier of wedding ... new collection of evening dresses for 2014. ... all these beautiful items are provided with big discounts, ... offer is July 22. , According to the ... to customer satisfaction. On the company’s website, sincere customer ...
(Date:7/11/2014)... 11, 2014 H.E.A.R Me Out Listens ... launches this week to provide comprehensive information and services ... half a million Coloradoans with hearing loss, this organization ... encompassing information of the local and state resources that ... hearing impaired. , H.E.A.R. Me Out and its website ...
Breaking Medicine News(10 mins):Health News:Exercise is the best medicine: QUT study 2Health News:Growing up on a livestock farm halves the risk of inflammatory bowel diseases 2Health News:Portland Fit Body Boot Camp Invites Public to Fitness Boot Camp Session Benefiting Children’s Cancer Association 2Health News:Portland Fit Body Boot Camp Invites Public to Fitness Boot Camp Session Benefiting Children’s Cancer Association 3Health News:Worldwide Chic Ladies Can Buy Cheap Evening Dresses at iFitDress.com 2Health News:H.E.A.R Me Out Listens to Needs of Hearing Impaired 2Health News:H.E.A.R Me Out Listens to Needs of Hearing Impaired 3
... CREEK, Mich., April 8, 2008 Diplomat ... the company as Director of,National Accounts. Maynard ... of Managed Markets., Maynard is responsible ... disease management programs, focusing initially on chronic,kidney ...
... Ill., April 8, 2008 The Northern Illinois,Fire Sprinkler ... a fire from spreading in a multi-unit building last ... the Chicago area., According to the Lake Zurich ... in a cardboard box where oily rags,thinner and paintbrushes ...
... rate when moms-to-be work out regularly , , TUESDAY, April 8 ... when the one exercising is a pregnant woman. , A ... reaps cardiac benefits. The benefits show up as lower fetal heart ... at the Experimental Biology 2008 annual meeting in San Diego. , ...
... who receive microwave therapy for enlarged prostates experience significant ... of a heart attack or stroke, according to new ... The Mayo Clinic-led study of 185 consecutive patients who ... that 42 percent experienced systolic blood pressure surges of ...
... in the most serious healthcare settings, even when patients are ... in the April issue of the UK-based Journal of Clinical ... and carrying out interviews with staff, patients and families in ... people with terminal illnesses. , They concluded that ...
... Board: CLAI), a leading provider of electronic transaction,services ... have signed,an agreement with Aetna to provide electronic ... Claimsnet will deliver claims,and receive Electronic Remittance Advice ... healthcare providers., "Claimsnet is extremely pleased to ...
Cached Medicine News:Health News:Diplomat Specialty Pharmacy Hires National Accounts Director To Expand Kidney Disease Services 2Health News:Fire Sprinklers Prevented More Than a Dozen Major Fires This Year in Chicago Area 2Health News:Microwave treatments for enlarged prostate cause blood pressure surges 2Health News:Humor plays an important role in healthcare even when patients are terminally ill 2Health News:Humor plays an important role in healthcare even when patients are terminally ill 3Health News:Claimsnet Announces Agreement With Aetna for Electronic Claims and Remittance Processing 2
... The NMP22® Test Kit is a quantitative ... NMP22 protein. Healthy individuals generally have very small ... the level of NMP22 protein is often elevated ... even at early stages of the disease. The ...
... connect an infusion bag ... and then to a ... to conduct urodynamics studies. ... Medical Technologies infusion pumps. ...
Used for cystometry and urethral pressure profilometry. A loop is employed to enhance catheter retention and stabilization within the bladder. Supplied sterile in peel-open packages. Intended for one...
... Used for cystometry and urethral pressure ... for faster filling of the bladder ... Dual lumen catheter construction allows the ... is performed. Triple lumen catheter construction ...
Medicine Products: